naloxone, Nasal Spray and Emergent BioSolutions
BioSolutions' strategic turnaround plan and cost-cutting efforts are paving the way for profitability in 2025. Explore more ...
After its sudden rise and precipitous fall during the COVID-19 pandemic, Emergent BioSolutions is taking measured steps as it attempts to reestablish its unique role as a drug developer combating u | ...
Emergent BioSolutions Inc. is a biopharmaceutical company focused on protecting and enhancing life by developing and manufacturing vaccines and antibody therapeutics that are supplied to ...
HC Wainwright has initiated coverage of Emergent BioSolutions (NYSE:EBS) at buy, citing sales of the company's ...
Representative Steve Cohen (D-Tennessee) recently sold shares of Emergent BioSolutions Inc. (NYSE:EBS). In a filing disclosed on January 10th, the Representative disclosed that they had sold between ...
Hikma Pharmaceuticals (HKMPF) announces that it has entered an exclusive commercial partnership with Emergent BioSolutions (EBS) for the sale ...
Even after a flurry of corporate updates during the first two days of the J.P. Morgan Healthcare Conference, many more ...
HC Wainwright reiterated their buy rating on shares of Emergent BioSolutions (NYSE:EBS – Free Report) in a research note issued to investors on Friday morning,Benzinga reports. They currently have a ...
While some are satisfied with an index fund, active investors aim to find truly magnificent investments on the ...
Emergent BioSolutions (EBS) announced that the Biomedical Advanced Research and Development Authority executed a contract modification for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback